Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on December 30, 2015. The filing addresses significant changes in the company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a new Principal Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of Officer: Douglas Beck, the Company's Chief Financial Officer, mutually agreed to terminate his employment without cause effective December 30, 2015. He is entitled to severance consisting of six months of base salary and health benefits.
- Appointment of Officer: Kulendiran Purushothaman was named Principal Financial Officer effective December 31, 2015. He previously served as the Company's Vice President of Finance since March 2015.
Compensation, Outlook, and Risks
Compensatory Arrangements for Mr. Purushothaman
- Base Salary: Increased to $180,000 annually effective December 31, 2015. Subject to satisfactory performance, this will increase to $200,000 effective July 1, 2016.
- Bonus: Eligible for an executive bonus program with a target of 20% of base salary. Upon attainment of objectives, the target bonus is set to increase to 25% of base salary effective July 1, 2016.
- Equity Grants: Received an initial grant of 20,000 stock options and 20,000 restricted shares. Vesting occurs over four years (25% after one year, then 6.25% quarterly).
- Termination Provisions: Employment is "at-will." Termination other than for cause entitles Mr. Purushothaman to accrued compensation, three months of base salary, and three months of health plan participation.
- Non-Solicitation: A 24-month non-solicitation clause applies to employees and clients following cessation of employment.
Risks and Contingencies
The filing notes that the Company has no related party transactions with Mr. Purushothaman and no family relationships between directors and officers. The primary operational risk highlighted is the transition of financial leadership.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 20,000 stock options granted to Mr. Purushothaman.
- Confirm the total cash severance amount paid to the departing CFO, Douglas Beck, based on his final base salary.
- Review the specific performance objectives required to trigger the 20% and 25% bonus targets for the new Principal Financial Officer.
- Check subsequent filings to confirm if the salary increase to $200,000 was implemented as scheduled on July 1, 2016.